ENTITY
BeiGene

BeiGene (BGNE US)

131
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
13 Mar 2023 09:21

Pdd/3690.hk/700.hk/1877HK/BGNE:PDD Enters Local Life Services Business

PDD enters local life services business;HOK International Version first launches in Brazil; Coherus announce FDA inspection of Toripalimab...

Share
bearishBeiGene
06 Mar 2023 08:55

BeiGene (6160.HK/BGNE.US) - Miracles Don't Always Happen

It’s unrealistic to be breakeven by relying on BRUKINSA alone considering the high unmanageable expenses. BeiGene needs three US$1 billion...

Logo
358 Views
Share
02 Mar 2023 18:20

JF Wealth Holdings IPO - Can Get Similar Exposure at Cheaper Valuations

JF Wealth Holdings (9636 HK) is looking to raise US$143m in its Hong Kong IPO. In this note, we discuss our earnings estimates, and thoughts on...

Logo
276 Views
Share
02 Mar 2023 09:09

JF Wealth IPO - Has Grown Well over Track Period, but Questions on Sustainability Remain

JF Wealth Holdings (9636 HK) is looking to raise US$143m in its Hong Kong IPO. JFW focuses on the online investor content services market in China.

Logo
247 Views
Share
x